AIDS

Bloodshot Billboards: Eye Syphilis is Serious

Retrieved on: 
tisdag, maj 7, 2024
AIDS, Health, General Health, Healthcare Reform, Public Policy, Pharmaceutical, Other Policy Issues, Public Safety, Infectious Diseases, Hospitals, Government, Syphilis, Woman, MSM, CDC, Paratriathlon, URL, PLWH, CNN, STI, Patient, AIDS Healthcare Foundation, Floater, Multimedia, HIV, AHF, Pharmaceutical industry

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Cases of syphilis are on the rise nationwide, and according to CNN , researchers in Chicago found more than two dozen cases last year of patients reporting unusual symptoms, such as vision and eye problems consistent with ocular syphilis.
  • “Syphilis itself is at an all-time high, and cases of ocular syphilis are likely to be underreported,” said Dr. Michael Dube, National Medical Director for AHF’s Public Health Division.
  • All five women had ocular syphilis from sexual contact with the same man who had asymptomatic syphilis.
  • If a client diagnosed with syphilis has any new issues with their eyes, they should be screened for ocular syphilis.

Soleo Health Selected as a Specialty Pharmacy Partner of RYPLAZIM® for Plasminogen Deficiency Type 1 (PLGD-1) Treatment

Retrieved on: 
måndag, maj 6, 2024
Professional Services, Other Science, Research, Science, Practice Management, Nursing, Medical Supplies, Other Health, Managed Care, FDA, General Health, Diabetes, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Software, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, AIDS, Technology, Health, Surgery, Insurance, Plasmin, Patient, Food and Drug Administration, Complex, Pharmacy, Partnership, Food, Pharmaceutical industry

RYPLAZIM is the first and only Food & Drug Administration (FDA)-approved treatment for supporting the approximately 500 people in the U.S. affected by plasminogen deficiency type 1 (PLGD-1).

Key Points: 
  • RYPLAZIM is the first and only Food & Drug Administration (FDA)-approved treatment for supporting the approximately 500 people in the U.S. affected by plasminogen deficiency type 1 (PLGD-1).
  • "We at Kedrion Biopharma appreciate our ongoing partnership with Soleo Health, especially with our latest specialty pharmaceutical, RYPLAZIM.
  • "We take pride in being among the few selected specialty pharmacy providers administering RYPLAZIM to PLGD-1 patients.
  • For more information about receiving RYPLAZIM therapy and services through Soleo Health, contact the Company at phone 844.547.8600 or fax 380.257.2419.

Pandemic Accord Is 20% Health Equity and 80% Inequity, Says AHF

Retrieved on: 
tisdag, maj 7, 2024
AIDS, Public Policy, Government, Health, Infectious Diseases, Other Policy Issues, Advocacy Group Opinion, COVID-19, Public, University, PABS, Language, WHO, International Monetary Fund, World Health Organization, Policy, Infection, Research, Comment, Vaccine, Pressure, Developed country, IMF, AIDS Healthcare Foundation, AHF

Specifically, the comment refers to Article 12 of the Accord, which deals with the World Health Organization (WHO) Pathogen Access and Benefit-Sharing System (PABS).

Key Points: 
  • Specifically, the comment refers to Article 12 of the Accord, which deals with the World Health Organization (WHO) Pathogen Access and Benefit-Sharing System (PABS).
  • “According to the International Monetary Fund (IMF), there are currently 152 developing countries where 6.82 billion people live, or 85.4% of the world's population.
  • If we fail to enshrine equity as a fundamental principle of global public health, all countries will be forced to pay many times over.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

Deadliest Mpox Crisis Demands Global Action Now, says AHF

Retrieved on: 
måndag, maj 6, 2024
AIDS, Health, Infectious Diseases, Hospitals, Pharmaceutical, Biotechnology, DRC, AHF, AIDS Healthcare Foundation, Vaccine, History, Democratic republic

As the Democratic Republic of the Congo fights its deadliest mpox outbreak in history, AIDS Healthcare Foundation (AHF) urges global cooperation for the response to the fullest extent possible to ensure the DRC and the continent have adequate resources and equitable access to lifesaving vaccines.

Key Points: 
  • As the Democratic Republic of the Congo fights its deadliest mpox outbreak in history, AIDS Healthcare Foundation (AHF) urges global cooperation for the response to the fullest extent possible to ensure the DRC and the continent have adequate resources and equitable access to lifesaving vaccines.
  • According to the Africa Centres for Disease Control and Prevention, mpox is endemic in 12 African countries.
  • “The current mpox outbreak is worrisome on multiple levels.
  • This outbreak deserves the world’s urgent and immediate attention,” said AHF Africa Bureau Chief Dr. Penninah Iutung.

AHF Backs FTC Challenge to Big Pharma Junk Patents

Retrieved on: 
fredag, maj 3, 2024
Advocacy Group Opinion, Public Policy, Government, Healthcare Reform, AIDS, White House, Federal Government, Health, Pharmaceutical, General Health, Other Policy Issues, Public, FTC, United, Weight loss, Patent, GSK, AIDS Healthcare Foundation, HIV, AHF, Asthma, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for anticompetitive use of so-called junk patents that prevent generic competition and keep drug prices artificially high.

Key Points: 
  • AIDS Healthcare Foundation (AHF) voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for anticompetitive use of so-called junk patents that prevent generic competition and keep drug prices artificially high.
  • “Big pharma is abusing the patent system by filing multiple derivative patents on existing drugs – which is not innovation – it’s greed.
  • AHF has worked closely with civil society partners to address these abuses.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240503187473/en/

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 2, 2024
AIDS, Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Infection, HIV Vaccine Trials Network, Administration, Cirrhosis, ASPR, Bangladesh Technical Education Board, Congress, HHS, COVID, EASL, Investment, Safety, Peginterferon-alfa, Abstract, MedRxiv, Development, Hepatitis, GSK, Vir, HCMV, Bill, Data analysis, Influenza, Conditional sentence, HIV, MBA, Metapneumovirus, Vaccine

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
  • The Phase 2 MARCH Part B trial is fully enrolled with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Cash, cash equivalents and investments declined by approximately $118 million during the first quarter of 2024.
  • Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023.

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

Retrieved on: 
torsdag, maj 2, 2024
Surgery, Science, Other Health, Veterinary, Nursing, Medical Supplies, Radiology, FDA, Other Science, Pharmaceutical, Diabetes, Research, Optical, Oncology, Mental Health, Medical Devices, Stem Cells, Infectious Diseases, Health Technology, Practice Management, Hospitals, Physical Therapy, Genetics, Managed Care, Fitness & Nutrition, Dental, Clinical Trials, Cardiology, Biotechnology, Alternative Medicine, AIDS, Health, Immunoglobulin G, Automation, ADAS, Safety, Pharmacokinetics, Animal, Primate, Software, Therapy, Litre, Toxicokinetics, Drug development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.

Key Points: 
  • Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.
  • The Gyrolab Generic Rodent ADA Kit fills an industry-wide need for a generic assay solution to expedite immunogenicity assessment.
  • Following the introduction of Gyrolab Generic Cyno ADA Kit Reagents, the Gyrolab Generic Rodent ADA Kit Reagents further expand the utility of the Gyrolab platform into earlier drug screening and preclinical phases of development.
  • Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The addition of the Gyrolab Generic Rodent ADA Kit Reagents to our portfolio enhances our offering of ready-to-use kits and solutions for use in drug screening and preclinical development.

MAY 1st IS INTERNATIONAL JOCKSTRAP APPRECIATION DAY!

Retrieved on: 
onsdag, maj 1, 2024
Hammerstein Ballroom, Jockstrap, AIDS, Hope, Meal, Brooks Brothers, Broadway Cares/Equity Fights AIDS, LEE, HIV/AIDS, Gold

NEW YORK, May 1, 2024 /PRNewswire/ -- On Wednesday, May 1st, BIKE Athletic invited some of Broadway's finest men to Times Square to shimmy and shake, dance and disrobe down to their jockstraps in celebration of the 150th Anniversary of the Jockstrap and Jockstrap Appreciation Day. These talented men are dancers from Broadway Bares, the annual, larger-than-life burlesque production that's produced by and benefits Broadway Cares/Equity Fights AIDS.

Key Points: 
  • NEW YORK, May 1, 2024 /PRNewswire/ -- On Wednesday, May 1st, BIKE Athletic invited some of Broadway's finest men to Times Square to shimmy and shake, dance and disrobe down to their jockstraps in celebration of the 150th Anniversary of the Jockstrap and Jockstrap Appreciation Day.
  • 2024 marks the 150th Anniversary of the Jockstrap.
  • HISTORY: The jockstrap was invented by C. F. Bennett to protect bicycle jockeys riding cobblestone streets.
  • The structure and comfort provided by the jockstrap led to the birth of modern men's underwear.

Minister of Justice and Attorney General of Canada announces judicial appointments to the Federal Court

Retrieved on: 
onsdag, maj 1, 2024
Public policy, AIDS, Mentorship, Metropolitan, Amnesty International, Legislation, Commerce, Rainbow Railroad, Associate, Person, University, Law society, Dignity, Woman, Law Society of Ontario, Criminal code, Survivor, Federal court, Supreme, Global Affairs Canada, Family, Community service, The Criminal Code, Questionnaire, Justice, Faculty, Faculty (division), Student, Government, Department of Justice (Canada), Disability, Language, Judiciary Act of 1925, Tax court, Supreme court, LL.B, Egale Canada, Senior, Cabinet, Richard Wagner (judge)

Justice Battista replaces Justice E. Walker, who was elevated to the Federal Court of Appeal on January 26, 2024.

Key Points: 
  • Justice Battista replaces Justice E. Walker, who was elevated to the Federal Court of Appeal on January 26, 2024.
  • Catharine Moore, Senior General Counsel at the Department of Justice Canada in Ottawa, is appointed an associate judge of the Federal Court.
  • This includes 103 appointments since the Honourable Arif Virani became Minister of Justice and Attorney General of Canada on July 26, 2023.
  • Federal judicial appointments are made by the Governor General, acting on the advice of the federal Cabinet and recommendations from the Minister of Justice.

Resource-Appropriate Cancer Care, Including Coexisting Health Issues of HIV and Cancer, to be Addressed During Meeting in Nairobi

Retrieved on: 
onsdag, maj 1, 2024
Cancer, NCCN, AIDS, ACC, Safety, American Cancer Society, Uganda Cancer Institute, HIV/AIDS, ACS, CHAI, Senior, Clinton Foundation, Patient, MPH, Drug, HIV, MBA, Kaposi's sarcoma, Non-Hodgkin lymphoma, Dietary supplement

NAIROBI, Kenya, May 1, 2024 /PRNewswire/ -- Local and global experts are meeting in Nairobi, Kenya to update clinical practice guidelines as part of ongoing work with Allied Against Cancer—a collaboration between the National Comprehensive Cancer Network® (NCCN®), African Cancer Coalition (ACC), American Cancer Society (ACS), and Clinton Health Access Initiative (CHAI). The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics. The event runs from May 1-3, 2024.

Key Points: 
  • The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics.
  • "Many cancers occur more frequently in people with HIV and AIDS, including AIDS-defining cancers like non-Hodgkin lymphoma, Kaposi sarcoma, and invasive cervical cancer.
  • The NCCN Harmonized Guidelines™ employ color-coded recommendations to delineate the best possible cancer care across various settings and resource availability.
  • The Nairobi meeting will focus on updates to the NCCN Harmonized Guidelines™ for People Living with HIV, as well as the following cancer types: